In a pair of hefty opinions, a federal judge has certified class action antitrust claims against pharmaceutical giant GlaxoSmithKline, maker of the wildly popular antidepressant drug Wellbutrin XL, for allegedly using sham patent suits to delay generic versions of the drug from making their way to the market.
In her two opinions in In re Wellbutrin XL Antitrust Litigation , U.S. District Judge Mary A. McLaughlin certified a class of direct purchasers and a class of indirect purchasers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]